CRISPR Therapeutics AG

Headquarters: Zug, Switzerland

Founded: 2013

Employees: 473

CEO: Dr. Samarth Kulkarni


Market Cap

$4.51 Billion

USD as of July 1, 2024

Market Cap History

CRISPR Therapeutics AG market capitalization over time

Evolution of CRISPR Therapeutics AG market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of CRISPR Therapeutics AG

Detailed Description

CRISPR Therapeutics AG, a gene-editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene-editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies; CTX120, an investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. In addition, the company develops regenerative medicine programs; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. The company was formerly known as Inception Genomics AG and changed its name to CRISPR Therapeutics AG in April 2014. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Top 1-year algo backtest: +207.50%

$10,000 in July 2023 would now be $30,750 by following this algorithm daily at market close.

Boost your returns with Disfold DeepFinance... Now!

Try Disfold DeepFinance FREE

Stocks & Indices

CRISPR Therapeutics AG has the following listings and related stock indices.

Stock: NASDAQ: CRSP wb_incandescent

Stock: BMV: CRSPN wb_incandescent

Key People

Founder(s): Emmanuelle Charpentier, Shaun Foy and Rodger Novak

Samarth Kulkarni (CEO)


Revenue: US$289.59 million (2019)

Operating income: US$46.74 million (2019)

Net income: US$46.74 million (2019)

Total assets: US$1.067 billion (2019)



Baarerstrasse 14

Zug, 6300


Phone: 41 41 561 3277